Public Employees Retirement System of Ohio grew its stake in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 1.6% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 151,163 shares of the biopharmaceutical company’s stock after purchasing an additional 2,394 shares during the period. Public Employees Retirement System of Ohio owned approximately 0.07% of Alexion Pharmaceuticals worth $18,392,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in ALXN. Wealthsource Partners LLC increased its position in shares of Alexion Pharmaceuticals by 4.4% during the second quarter. Wealthsource Partners LLC now owns 3,002 shares of the biopharmaceutical company’s stock worth $365,000 after acquiring an additional 126 shares in the last quarter. National Asset Management Inc. increased its position in shares of Alexion Pharmaceuticals by 5.1% during the second quarter. National Asset Management Inc. now owns 3,345 shares of the biopharmaceutical company’s stock worth $407,000 after acquiring an additional 162 shares in the last quarter. Asymmetry Capital Management L.P. bought a new stake in shares of Alexion Pharmaceuticals during the second quarter worth about $1,486,000. Piedmont Investment Advisors LLC increased its position in shares of Alexion Pharmaceuticals by 1.0% during the second quarter. Piedmont Investment Advisors LLC now owns 46,533 shares of the biopharmaceutical company’s stock worth $5,662,000 after acquiring an additional 446 shares in the last quarter. Finally, Raymond James Financial Services Advisors Inc. increased its position in shares of Alexion Pharmaceuticals by 9.0% during the second quarter. Raymond James Financial Services Advisors Inc. now owns 34,782 shares of the biopharmaceutical company’s stock worth $4,232,000 after acquiring an additional 2,871 shares in the last quarter. Hedge funds and other institutional investors own 94.25% of the company’s stock.

Shares of Alexion Pharmaceuticals, Inc. (ALXN) traded up 0.9816% during mid-day trading on Tuesday, hitting $142.2225. 226,214 shares of the company were exchanged. The company has a 50 day moving average of $142.24 and a 200 day moving average of $127.19. The company has a market capitalization of $31.74 billion, a P/E ratio of 61.6750 and a beta of 1.39. Alexion Pharmaceuticals, Inc. has a 52 week low of $96.18 and a 52 week high of $149.34.

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.08 by $0.48. The company had revenue of $912.00 million during the quarter, compared to analyst estimates of $846.15 million. Alexion Pharmaceuticals had a net margin of 15.31% and a return on equity of 12.47%. The firm’s quarterly revenue was up 21.1% compared to the same quarter last year. During the same period in the previous year, the business posted $1.13 earnings per share. Equities analysts anticipate that Alexion Pharmaceuticals, Inc. will post $5.60 earnings per share for the current year.

In related news, Director Ann M. Veneman sold 700 shares of the business’s stock in a transaction that occurred on Monday, July 31st. The shares were sold at an average price of $137.74, for a total transaction of $96,418.00. Following the completion of the sale, the director now directly owns 6,315 shares in the company, valued at $869,828.10. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Julie O’neill sold 11,160 shares of the business’s stock in a transaction that occurred on Monday, August 28th. The shares were sold at an average price of $140.00, for a total transaction of $1,562,400.00. Following the sale, the executive vice president now owns 26,704 shares of the company’s stock, valued at $3,738,560. The disclosure for this sale can be found here. Insiders have sold 17,190 shares of company stock valued at $2,433,669 over the last 90 days. 4.35% of the stock is currently owned by company insiders.

ILLEGAL ACTIVITY NOTICE: This article was first reported by Watch List News and is the sole property of of Watch List News. If you are reading this article on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright legislation. The original version of this article can be accessed at https://www.watchlistnews.com/public-employees-retirement-system-of-ohio-increases-stake-in-alexion-pharmaceuticals-inc-alxn/1636633.html.

ALXN has been the subject of several recent research reports. BidaskClub raised shares of Alexion Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, June 20th. Leerink Swann reissued an “outperform” rating on shares of Alexion Pharmaceuticals in a research report on Thursday, June 22nd. Robert W. Baird reissued a “neutral” rating and set a $145.00 target price on shares of Alexion Pharmaceuticals in a research report on Monday, June 26th. UBS AG reissued a “buy” rating and set a $142.00 target price (up from $140.00) on shares of Alexion Pharmaceuticals in a research report on Monday, June 26th. Finally, Cowen and Company reissued an “outperform” rating and set a $122.00 target price on shares of Alexion Pharmaceuticals in a research report on Monday, July 3rd. Six equities research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and two have assigned a strong buy rating to the company. Alexion Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $154.56.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.